Should We Test for CYP2C9 Before Initiating Anticoagulant Therapy in Patients with Atrial Fibrillation?
- 3 March 2009
- journal article
- case report
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 24 (5) , 543-549
- https://doi.org/10.1007/s11606-009-0927-7
Abstract
No abstract availableKeywords
This publication has 67 references indexed in Scilit:
- Genetic-based dosing in orthopedic patients beginning warfarin therapyBlood, 2007
- Influence of CYP2C9 and VKORC1 1173C/T Genotype on the Risk of Hemorrhagic Complications in African-American and European-American Patients on WarfarinClinical Pharmacology & Therapeutics, 2007
- Death and Disability from Warfarin-Associated Intracranial and Extracranial HemorrhagesThe American Journal of Medicine, 2007
- Association of warfarin dose with genes involved in its action and metabolismHuman Genetics, 2006
- Age and the Risk of Warfarin‐Associated Hemorrhage: The Anticoagulation and Risk Factors In Atrial Fibrillation StudyJournal of the American Geriatrics Society, 2006
- The future prospects of pharmacogenetics in oral anticoagulation therapyBritish Journal of Clinical Pharmacology, 2006
- Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF)American Heart Journal, 2006
- Association of Apolipoprotein E4 and Haplotypes of the Apolipoprotein E Gene With Lobar Intracerebral HemorrhageStroke, 2005
- Health-Related Quality of Life After Stroke A Comprehensive ReviewStroke, 2001
- Oral Anticoagulants and Intracranial HemorrhageStroke, 1995